OLAPARIB
| Brand name | LYNPARZA |
|---|---|
| Active ingredient | OLAPARIB |
| Strength | 50MG |
| Dosage form | CAPSULE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | December 2014 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 8859562 | August 2031 | use U-1634 |
| 8247416 | September 2028 | substance |
| 8143241 | August 2027 | use U-1634 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.